Therapeutic ladder for pemphigus vulgaris: Emphasis on achieving complete remission

References 

1. Harman KE, Albert S, Black MM British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149:926–937
   • MEDLINE
   • CrossRef
2. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009;(1):CD006263
3. Azam U. Aspreva completes expanded patient enrollment in phase III clinical trial for CellCept in pemphigus vulgaris. Available from: http://www.medicalnewstoday.com/articles/71797.php. Accessed February 12, 2009.
4. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42:422–427
   • Abstract
   • Full Text
   • Full-Text PDF (44 KB)
   • CrossRef
5. Powell AM, Albert S, Al Fares S, Harman KE, Setterfield J, Bhogal B, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149:138–145
   • MEDLINE
   • CrossRef
6. Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol. 2003;13:377–381
   • MEDLINE
7. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol. 2002;147:261–265
   • MEDLINE
   • CrossRef
8. Dupuy A, Viguier M, Bédane C, Cordoliani F, Blaise S, Aucouturier F, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140:91–96
   • CrossRef
9. Bystyrn JC. Therapy of pemphigus. Semin Dermatol. 1988;7:186–194
10. Mortazavi H, Shahdi M, Amirzargar AA, Naraghi ZS, Valikhani M, Daneshpazhooh M, et al. Desmoglein ELISA in the diagnosis of pemphigus and its correlation with the severity of pemphigus vulgaris. Iran J Allergy Asthma Immunol. 2009;8:53–56